Anika Gupta

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.

Gene editing technologies have stirred the imaginations of scientists for close to a decade. Many companies are aspiring to disrupt chronic care models with single-dose, curative treatments for monogenic diseases. Others see gene editing becoming an increasingly important tool for rapidly recognizing novel pathogens for pandemic response. Emboldened by the latest clinical data from Cambridge, Mass.-based Intellia Therapeutics — which... Read More